Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12081988 | 0.90 | MEN1 (0.64) | HPGDGAAPKMTLR9MEN1 | |
| SCHEMBL22580612 | 0.90 | MEN1 (0.64) | HPGDGAAPKMTLR9MEN1 | |
| SCHEMBL17358738 | 0.88 | CTSG (0.61) | HPGDGAAPKMTLR9MEN1 | |
| SCHEMBL17717939 | 0.87 | ENPP2 (0.49) | HPGDGAAPKMTLR9MEN1 | |
| SCHEMBL5437358 | 0.86 | OPRK1 (0.56) | HPGDGAAPKMTLR9MEN1 | |
| SCHEMBL17717923 | 0.84 | MEN1 (0.56) | HPGDGAAPKMTLR9MEN1 | |
| SCHEMBL4422153 | 0.84 | HPGD (0.74) | HPGDGAAPKMTLR9MEN1 | |
| SCHEMBL11595767 | 0.82 | TSHR (0.47) | HPGDGAAPKMTLR9MEN1 | |
| SCHEMBL1165628 | 0.82 | HPGD (0.55) | HPGDGAAPKMTLR9MEN1 | |
| SCHEMBL11182628 | 0.82 | MGLL (0.62) | HPGDGAAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 657 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110028456-B | Barbituric acid derivative and preparation method and application thereof | 齐鲁工业大学 | 2021-02-23 | — | — | CN | claimed |
| CN-110028456-A | A kind of barbituric acid derivatives and preparation method and application | 齐鲁工业大学 | 2019-07-19 | — | — | CN | claimed |
| CN-105310888-B | Dental regulation composition | 株式会社松风 | 2019-05-21 | — | — | CN | claimed |
| US-20170348303-A1 | PHARMACEUTICAL COMPOSITIONS | CHARLESTON LABORATORIES, INC. | 2017-12-07 | — | — | US | claimed |
| US-9668943-B2 | Dental conditioning composition | KABUSHIKI KAISHA SHOFU (JP) | 2017-06-06 | — | — | US | claimed |
| US-8158639-B2 | Non-sedating barbiturate compounds as neuroprotective agents | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-04-17 | — | — | US | claimed |
| US-20100197709-A1 | NON-SEDATING BARBITURATE COMPOUNDS AS NEUROPROTECTIVE AGENTS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-08-05 | — | — | US | claimed |
| US-7723346-B2 | Non-sedating barbiturate compounds as neuroprotective agents | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-05-25 | — | — | US | claimed |
| US-7488762-B2 | Two paste-type glass ionomer cement | KABUSHIKI KAISHA SHOFU (JP) | 2009-02-10 | — | — | US | claimed |
| EP-1311270-B1 | NON-SEDATING BARBITURATE COMPOUNDS AS NEUROPROTECTIVE AGENTS | TARO PHARMA IND (IL) | 2008-01-09 | — | — | EP | claimed |
| US-20060205747-A1 | Non-sedating barbiturate compounds as neuroprotective agents | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-09-14 | — | — | US | claimed |
| EP-1311270-A4 | NON-SEDATING BARBITURATE COMPOUNDS AS NEUROPROTECTIVE AGENTS | TARO PHARMA IND (IL) | 2006-04-12 | — | — | EP | claimed |
| US-20040224947-A1 | Non-sedating barbiturate compounds as neuroprotective agents | TARO PHARMACEUTICAL INDUSTRIES LTD (IL) | 2004-11-11 | — | — | US | claimed |
| US-6756379-B2 | USING SUCH AS 1,3-DIMETHOXYMETHYL-5,5-DIPHENYL-BARBITURIC ACID | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-06-29 | — | — | US | claimed |
| US-20030153589-A1 | Non-sedating barbiturate compounds as neuroprotective agents | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-08-14 | — | — | US | claimed |
| EP-1311270-A1 | NON-SEDATING BARBITURATE COMPOUNDS AS NEUROPROTECTIVE AGENTS | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2003-05-21 | — | — | EP | claimed |
| WO-2002007729-A9 | NON-SEDATING BARBITURATE COMPOUNDS AS NEUROPROTECTIVE AGENTS | TARO PHARMA IND (IL) | 2002-08-08 | — | — | WO | claimed |
| WO-2002007729-A1 | NON-SEDATING BARBITURATE COMPOUNDS AS NEUROPROTECTIVE AGENTS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-01-31 | — | — | WO | claimed |
| US-RE31986-E | Manufacture of organic pigments | BASF AKTIENGESELLSCHAFT (DE) | 1985-09-17 | — | — | US | claimed |
| US-4166179-A | MANUFACTURE OF ORGANIC PIGMENTS | BASF AKTIENGESELLSCHAFT (DE) | 1979-08-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197709-A1 | NON-SEDATING BARBITURATE COMPOUNDS AS NEUROPROTECTIVE AGENTS | GABRB1, GABRB2, GABRB3 | HPGD 318/4885GAA 3085/4885PKM 2230/4885 |
| US-20060205747-A1 | Non-sedating barbiturate compounds as neuroprotective agents | GABRB1, GABRB2, GABRB3 | HPGD 318/4885GAA 3085/4885PKM 2230/4885 |
| US-20030153589-A1 | Non-sedating barbiturate compounds as neuroprotective agents | GABRB1, GABRB3, GABRB2 | HPGD 325/4885GAA 2899/4885PKM 2201/4885 |
| US-20040224947-A1 | Non-sedating barbiturate compounds as neuroprotective agents | GABRB1, GABRB2, GABRB3 | HPGD 318/4885GAA 3085/4885PKM 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.